Histogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing
02 oct. 2017 16h15 HE
|
Histogenics Corporation
– Data Demonstrate the Importance of Generating Extracellular Matrix During Ex-Vivo Manufacturing of Cartilage Cell Therapy – – Ex-vivo Production of Extracellular Matrix is Critical to...
Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa
26 sept. 2017 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the...
Histogenics Corporation to Present at Upcoming Investor Conferences
24 août 2017 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
10 août 2017 06h30 HE
|
Histogenics Corporation
‒ Completed Enrollment in NeoCart® Phase 3 Clinical Trial ‒‒ Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 ‒‒ Defined Regulatory Pathway with Japan Pharmaceuticals and...
Histogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting Study
11 juil. 2017 08h30 HE
|
Histogenics Corporation
– Findings Augment Growing Body of Information to Support the Manufacture of Current and Next-Generation NeoCart® Implants – – 3-D Bioprinting May Enable More Efficient Production of Next Generation...
Histogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage
27 juin 2017 16h01 HE
|
Histogenics Corporation
– On Track for Top-Line One Year Superiority Data and Potential BLA Filing in Third Quarter of 2018 – – Novel Tissue Implant Potentially Accelerates Recovery and Reduces Pain through Proprietary...